Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals develops, manufactures, and sells generic and proprietary injectable products. Products include BAQSIMI for severe hypoglycemia, Primatene Mist for mild asthma symptoms, Enoxaparin for deep vein thrombosis prevention, and REXTOVY and Naloxone for opioid overdose treatment. The company also offers a range of other injectable products, including anesthetics, analgesics, and diagnostic agents. Additionally, Amphastar develops generic product candidates and distributes recombinant human insulin APIs and porcine insulin API.

Overview

Sector

Pharmaceutical

Target Price

49.6 USD

Current Price

29.8 USD

Potential

67%

Strengths

With an appreciation Potential of 60.40%, based on our fundamental analysis, it suggests the stock may be undervalued.
Current Price to Earnings Ratio (9.02) is lower than the sector mean (289.29).
Price to book ratio (1.96) is lower than the sector mean (733.70).
EV/EBITDA (6.81) is lower than the sector mean (51.86).
EV/EBIT (8.58) is lower than the sector mean.
Price to free cash flow (8.35) is lower than the sector mean.
Strong EBITDA Margin of 38.90%.

Weaknesses

No significant weaknesses identified based on the analyzed metrics.

Key Financial Data

Indicator	Value
PER	8.9
EV/EBITDA	6.7
Price/Free Cash Flow'	8.2
ROIC	16.0%
Net Debt/EBITDA	1.6